Natera, Inc. $NTRA Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC cut its position in shares of Natera, Inc. (NASDAQ:NTRA) by 4.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 454,498 shares of the medical research company’s stock after selling 20,896 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.33% of Natera worth $104,007,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Integrated Wealth Concepts LLC increased its holdings in Natera by 6.6% during the 1st quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock valued at $221,000 after acquiring an additional 96 shares in the last quarter. NewEdge Advisors LLC increased its position in Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock worth $644,000 after buying an additional 1,847 shares in the last quarter. Focus Partners Wealth lifted its position in shares of Natera by 8.6% in the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock valued at $847,000 after acquiring an additional 474 shares in the last quarter. Sivia Capital Partners LLC purchased a new position in Natera in the 2nd quarter valued at about $298,000. Finally, New York State Common Retirement Fund boosted its stake in shares of Natera by 56.5% during the 2nd quarter. New York State Common Retirement Fund now owns 90,847 shares of the medical research company’s stock worth $15,348,000 after purchasing an additional 32,800 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

NTRA has been the topic of several analyst reports. Citigroup assumed coverage on Natera in a report on Wednesday, January 7th. They set a “buy” rating and a $300.00 price objective on the stock. Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Morgan Stanley decreased their price target on shares of Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. Guggenheim lifted their target price on Natera from $230.00 to $270.00 and gave the company a “buy” rating in a report on Monday, January 5th. Finally, JPMorgan Chase & Co. raised their price target on shares of Natera from $250.00 to $260.00 and gave the company an “overweight” rating in a report on Monday, December 15th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Natera currently has an average rating of “Moderate Buy” and an average price target of $253.47.

Insider Activity at Natera

In other Natera news, insider John Fesko sold 17,806 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $234.74, for a total transaction of $4,179,780.44. Following the sale, the insider owned 177,591 shares in the company, valued at $41,687,711.34. This represents a 9.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Steven Leonard Chapman sold 85,299 shares of Natera stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $230.72, for a total transaction of $19,680,185.28. Following the completion of the transaction, the chief executive officer directly owned 127,881 shares of the company’s stock, valued at approximately $29,504,704.32. This represents a 40.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 318,344 shares of company stock valued at $74,091,416. 5.63% of the stock is owned by insiders.

Natera Price Performance

Shares of NTRA stock opened at $199.99 on Wednesday. The company’s fifty day moving average price is $209.42 and its two-hundred day moving average price is $208.96. The firm has a market capitalization of $28.34 billion, a P/E ratio of -130.71 and a beta of 1.65. Natera, Inc. has a 12 month low of $125.38 and a 12 month high of $256.36.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, topping the consensus estimate of ($0.46) by $0.81. Natera had a negative return on equity of 15.28% and a negative net margin of 9.03%.The business had revenue of $665.50 million for the quarter, compared to analysts’ expectations of $600.68 million. During the same quarter in the previous year, the firm posted ($0.41) earnings per share. On average, sell-side analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.